AdvaMed announced today that it named Dexcom President and CEO Jake Leach as the new chair for the AdvaMed Diabetes Sector. Leach succeeds Abbott EVP of Diabetes Care, Chris Scoggins, in the position. Eric Benjamin, Insulet’s EVP and COO, will serve as the vice chair for the medical device industry association’s Diabetes Sector, which represents […]
Dexcom
Dexcom beats Street in Q4 on 13% sales growth
Dexcom (NSDQ:DXCM) shares ticked up after hours today on fourth-quarter results that came in ahead of the consensus forecast. Shares of DXCM rose 1% to $65.70 apiece in post-market trading today. The San Diego-based continuous glucose monitor (CGM) maker reported profits of $267.3 million. That equals 68¢ per share on sales of $1.259 billion for […]
New Dexcom CEO Jake Leach talks 2026 roadmap, next-gen tech
After more than 100 days in the corner office at CGM maker Dexcom (NSDQ:DXCM), CEO Jake Leach is excited for the company’s future. In July, Leach was tapped to take the CEO role permanently at the start of 2026 as part of Dexcom’s planned succession process. He took over a few months early as outgoing […]
Dexcom stock rises on Street-beating preliminary Q4 sales
Dexcom (NSDQ:DXCM) today announced preliminary fourth-quarter results that included revenues that topped the consensus forecast. For the quarter ended Dec. 31, 2025, the company expects total revenue of $1.26 billion. That marks a 13% increase over the same period a year ago and lands just ahead of expectations on Wall Street. Dexcom expects to report […]
Dexcom touts future at CES with new CEO Leach now leading
Dexcom (NSDQ:DXCM) today announced the beginning of new CEO Jake Leach’s tenure, starting with his presence at CES 2026. Leach assumed the role of CEO officially on Jan. 1. He has been serving as CEO in an interim capacity since his predecessor, Kevin Sayer, took a leave of absence in September. In July, the company […]
The top diabetes tech stories of 2025
As the year comes to a close, it’s time to look back at the numerous innovations across the diabetes technology industry in 2025. Once again, continuous glucose monitors (CGMs) and automated insulin delivery systems took most of the headlines, as the leaders in the space keep building on their platforms while challengers continue to enter […]
Dexcom to cease G6 CGM production next year, transition fully to G7
A Dexcom (NSDQ:DXCM) communication on its website states that it will soon cease manufacturing for its G6 continuous glucose monitor (CGM). After July 1, 2026, the company plans to no longer manufacture the G6, its previous-generation CGM. This marks a transition to the company’s latest-generation G7, and perhaps an eventual look ahead to future CGMs. […]
Beta Bionics makes iLet available with Dexcom G7 15 Day CGM
Beta Bionics (Nasdaq:BBNX) took to social media to announce the integration of its iLet Bionic Pancreas with Dexcom’s (Nasdaq:DXCM) G7 15 Day continuous glucose monitor (CGM). Dexcom received FDA clearance for people over the age of 18 years old in the U.S. in April for the 15-day version of its latest-generation sensor. Last month, the company announced its […]
Dexcom launches program to enhance healthcare provider CGM knowledge
Dexcom (Nasdaq:DXCM) today announced the launch of Dexcom Academy, a new, personalized learning platform for healthcare professionals (HCPs). Guided by HCP insights, the company designed Dexcom Academy to strengthen confidence in continuous glucose monitor (CGM) use. The San Diego-based CGM maker wants to support consistent, high-quality diabetes care without adding to clinical burden. The company […]
Insulet makes Omnipod 5 available with Dexcom G7 15 Day CGM
Insulet (Nasdaq:PODD) today announced immediate compatibility between its Omnipod 5 system and the Dexcom (Nasdaq:DXCM) G7 15 Day CGM. Acton, Massachusetts-based Insulet, which has paired its pumps with previous versions of Dexcom continuous glucose monitors (CGMs), has offered Omnipod 5 with the initial version of G7 since early 2024. However, Dexcom received FDA clearance for people […]
